Management of Pediatric Wheezing and Bronchitis
For children with chronic wet cough and wheezing (bronchitis), initiate a 2-week course of antibiotics targeting common respiratory bacteria (amoxicillin-clavulanate), and if symptoms resolve, diagnose protracted bacterial bronchitis (PBB); for children with episodic viral wheeze or multiple-trigger wheeze, use short-acting beta-2 agonists as first-line therapy. 1, 2, 3
Initial Clinical Assessment and Phenotype Classification
The first critical step is distinguishing between wet cough/bronchitis versus wheezing phenotypes:
Wet Cough (Protracted Bacterial Bronchitis)
- Daily wet/productive cough lasting >4 weeks
- No specific warning signs (digital clubbing, feeding-related cough, failure to thrive)
- Most common bacterial pathogens: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
Wheezing Phenotypes
- Episodic viral wheeze: Wheeze only during viral respiratory infections, symptom-free between episodes
- Multiple-trigger wheeze: Wheeze triggered by multiple factors (viruses, allergens, exercise, cold air)
Treatment Algorithm
For Chronic Wet Cough/Bronchitis (PBB)
Initial Management:
- Start amoxicillin-clavulanate for 2 weeks (dose appropriate for local antibiotic sensitivities) 1
- If cough resolves within 2 weeks → Diagnose as PBB 1
- If cough persists after 2 weeks → Extend antibiotics for additional 2 weeks (total 4 weeks) 1
If symptoms persist after 4 weeks of appropriate antibiotics:
- Proceed to further investigations: flexible bronchoscopy with quantitative cultures, chest CT scan 1
- Consider underlying diseases (aspiration, immunodeficiency, structural abnormalities)
Common Pitfall: Cycling through short antibiotic courses (5-7 days) that fail to adequately treat the bacterial infection. PBB requires minimum 2 weeks, often extending to 4 weeks. 4
For Wheezing Without Wet Cough
Episodic Viral Wheeze:
- Short-acting beta-2 agonists (salbutamol) via spacer device as first-line for acute episodes 2, 3
- Bronchodilators provide symptomatic relief during viral infections
- Do NOT use: Maintenance inhaled corticosteroids (ineffective in pure episodic viral wheeze) 5
- Do NOT use: Antibiotics (viral etiology) 2
- Consider intermittent high-dose inhaled corticosteroids or montelukast for frequent, moderately severe episodes 5
Multiple-Trigger Wheeze:
- Short-acting beta-2 agonists for acute symptoms 3
- Low-to-moderate dose maintenance inhaled corticosteroids may be tried for symptom control 2, 5
- Montelukast has a role in both maintenance and intermittent treatment 5
- Trial therapy for 4-8 weeks, then reassess; discontinue if no benefit
When to Investigate Further
Immediate referral/investigation needed for:
- Symptoms present from early infancy
- Digital clubbing
- Failure to thrive or systemic involvement
- Feeding-related cough (aspiration risk)
- Suspected foreign body aspiration
- Anaphylaxis 6
For persistent wheezing despite standard treatment (bronchodilators, inhaled/systemic corticosteroids):
- Consider flexible bronchoscopy with airway survey to identify anatomic abnormalities (tracheomalacia, vascular rings, foreign bodies) - found in ~33% of cases 7
- Consider bronchoalveolar lavage (BAL) - 40-60% of persistent wheezers have positive bacterial cultures; 20-30% improve with targeted antibiotic therapy 7
- Video-fluoroscopic swallowing study if aspiration suspected 7
Critical Distinctions
Bronchiolitis vs. Wheezy Bronchitis:
- Bronchiolitis (typically infants <12 months, RSV): Supportive care only; bronchodilators, corticosteroids, and antibiotics are NOT recommended 2, 3
- Wheezy bronchitis (preschool children, recurrent episodes): Bronchodilators are effective 3
What NOT to Do:
- Do not use antitussive medications (ineffective) 3
- Do not empirically avoid foods without eczema present 7
- Do not use routine chest X-rays or extensive laboratory testing for typical presentations 2
- Do not use inhaled corticosteroids for pure episodic viral wheeze 5
Evidence Quality Note
The 2017 CHEST guideline 1 provides Grade 1A evidence (high quality) for antibiotic treatment of chronic wet cough, representing the strongest available evidence for PBB management. The American Thoracic Society guidelines 7 acknowledge very low quality evidence for bronchoscopy recommendations, making these conditional suggestions for persistent cases only. The distinction between wet cough (bacterial) and wheeze (often viral or asthma-related) is fundamental to appropriate management.